to Lectin Pathway Activation and -2: Significant Contribution of MASP-1 Lectin-Associated Serine Protease (MASP)-1 Peptides against Mannose-Binding Complement with Phage Display Selected Selective Inhibition of the Lectin Pathway of

The complement system, an essential part of the innate immune system, can be activated through three distinct routes: the classical, the alternative, and the lectin pathways. The contribution of individual activation pathways to different biological processes can be assessed by using pathway-selective inhibitors. In this paper, we report lectin pathway-specific short peptide inhibitors developed by phage display against mannose-binding lectin-associated serine proteases (MASPs), MASP-1 and MASP-2. On the basis of the selected peptide sequences, two 14-mer peptides, designated as sunflower MASP inhibitor (SFMI)-1 and SFMI-2, were produced and characterized. SFMI-1 inhibits both MASP-1 and MASP-2 with a K I of 65 and 1030 nM, respectively, whereas SFMI-2 inhibits only MASP-2 with a K I of 180 nM. Both peptides block the lectin pathway activation completely while leaving the classical and the alternative routes intact and fully functional, demonstrating that of all complement proteases only MASP-1 and/or MASP-2 are inhibited by these peptides. In a C4 deposition inhibitor assay using preactivated MASP-2, SFMI-2 is 10-fold more effective than SFMI-1 in accordance with the fact that SFMI-2 is a more potent inhibitor of MASP-2. Surprisingly, however, out of the two peptides, SFMI-1 is much more effective in preventing C3 and C4 deposition when normal human serum containing zymogen MASPs is used. This suggests that MASP-1 four different enzymes: MASP-1, MASP-2, trypsin, and thrombin. A method developed for determining the equilibrium K I values of tight binding inhibitors was applied (36). A thioesther substrate, Z-L-LysSBzl hydrochloride (C3647; Sigma-Aldrich), was used in the photometric assay. MASP-1, MASP-2, or trypsin was incubated with serial dilutions of the inhibitors for 1 h at room temperature. The reactions were conducted in 1 ml final volume at room temperature in 20 mM HEPES, 145 mM NaCl, 5 mM CaCl 2 , and 0.05% Triton X-100 (pH 7.6). The sulfhydryl of the cleaved substrate reacted with the cosubstrate dithiopyridine (143057; Sigma-Aldrich) producing the product detected at 324 nm. Enzyme concentration of the stock prote- ase solutions was determined by active site titration. In the case of trypsin and thrombin 4-methylumbelliferyl-4-guanidinobenzoate (51010; Sigma- Aldrich), whereas in the case of MASP-1 and MASP-2, a C1 inhibitor was used for the titration. The concentration of the free enzyme in the inhibitory assay was determined by the ratio of the residual enzyme activity (in the presence of inhibitor) and the total enzyme hibitor). The K I values were determined by nonlinear regression analysis the following

[1]  K. Skjødt,et al.  MBL-associated serine protease-3 circulates in high serum concentrations predominantly in complex with Ficolin-3 and regulates Ficolin-3 mediated complement activation. , 2010, Immunobiology.

[2]  A. Sahu,et al.  Identification of Complin, a Novel Complement Inhibitor that Targets Complement Proteins Factor B and C2 , 2010, The Journal of Immunology.

[3]  A. Krarup,et al.  Activation of mannan‐binding lectin‐associated serine proteases leads to generation of a fibrin clot , 2010, Immunology.

[4]  K. Skjødt,et al.  A Novel Mannose-binding Lectin/Ficolin-associated Protein Is Highly Expressed in Heart and Skeletal Muscle Tissues and Inhibits Complement Activation* , 2010, The Journal of Biological Chemistry.

[5]  M. Frank,et al.  Therapeutic potential of complement modulation , 2010, Nature Reviews Drug Discovery.

[6]  R. Wallis,et al.  Paths reunited: Initiation of the classical and lectin pathways of complement activation. , 2010, Immunobiology.

[7]  John D Lambris,et al.  Recent developments in low molecular weight complement inhibitors. , 2009, Molecular immunology.

[8]  S. Thiel,et al.  MAp44, a Human Protein Associated with Pattern Recognition Molecules of the Complement System and Regulating the Lectin Pathway of Complement Activation1 , 2009, The Journal of Immunology.

[9]  P. Gál,et al.  Early complement proteases: C1r, C1s and MASPs. A structural insight into activation and functions. , 2009, Molecular immunology.

[10]  P. Gál,et al.  Complement protease MASP-1 activates human endothelial cells: PAR4 activation is a link between complement and endothelial function , 2009 .

[11]  P. Garred,et al.  MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. , 2009, Molecular immunology.

[12]  P. Gál,et al.  MASP-1, a Promiscuous Complement Protease: Structure of Its Catalytic Region Reveals the Basis of Its Broad Specificity1 , 2009, The Journal of Immunology.

[13]  P. Gál,et al.  C1, MBL-MASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammation. , 2008, Trends in molecular medicine.

[14]  A. Krarup,et al.  The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen. , 2008, Biochimica et biophysica acta.

[15]  K. Werdan,et al.  Serine Protease Inhibitor Nafamostat Given Before Reperfusion Reduces Inflammatory Myocardial Injury by Complement and Neutrophil Inhibition , 2008, Journal of cardiovascular pharmacology.

[16]  A. Jaśkiewicz,et al.  Peptomeric analogues of trypsin inhibitor SFTI-1 isolated from sunflower seeds. , 2008, Bioorganic & medicinal chemistry.

[17]  Shigeto Miura,et al.  Mannose-Binding Lectin (MBL)-Associated Serine Protease (MASP)-1 Contributes to Activation of the Lectin Complement Pathway , 2008 .

[18]  John D. Lambris,et al.  The Classical Complement Cascade Mediates CNS Synapse Elimination , 2007, Cell.

[19]  John D Lambris,et al.  Complement-targeted therapeutics , 2007, Nature Biotechnology.

[20]  S. Thiel Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. , 2007, Molecular immunology.

[21]  D. Hourcade,et al.  Properdin Can Initiate Complement Activation by Binding Specific Target Surfaces and Providing a Platform for De Novo Convertase Assembly1 , 2007, The Journal of Immunology.

[22]  L. Gráf,et al.  When the surface tells what lies beneath: combinatorial phage-display mutagenesis reveals complex networks of surface-core interactions in the pacifastin protease inhibitor family. , 2007, Journal of molecular biology.

[23]  P. Gál,et al.  Serine proteases of the classical and lectin pathways: similarities and differences. , 2007, Immunobiology.

[24]  S. Thiel,et al.  Cooperation between MASP-1 and MASP-2 in the generation of C3 convertase through the MBL pathway. , 2006, International immunology.

[25]  John D Lambris,et al.  Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. , 2006, Journal of medicinal chemistry.

[26]  D. Craik,et al.  Discovery, Structural Determination, and Putative Processing of the Precursor Protein That Produces the Cyclic Trypsin Inhibitor Sunflower Trypsin Inhibitor 1* , 2005, Journal of Biological Chemistry.

[27]  A. Sjöholm,et al.  Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. , 2005, Journal of immunological methods.

[28]  G. Ambrus,et al.  The structure of MBL-associated serine protease-2 reveals that identical substrate specificities of C1s and MASP-2 are realized through different sets of enzyme-substrate interactions. , 2004, Journal of molecular biology.

[29]  G. Crooks,et al.  WebLogo: a sequence logo generator. , 2004, Genome research.

[30]  K. Hajela,et al.  Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. , 2004, Molecular immunology.

[31]  R. Leatherbarrow,et al.  The conserved P1' Ser of Bowman-Birk-type proteinase inhibitors is not essential for the integrity of the reactive site loop. , 2003, Biochemical and biophysical research communications.

[32]  D. Craik,et al.  Enzymatic Cyclization of a Potent Bowman-Birk Protease Inhibitor, Sunflower Trypsin Inhibitor-1, and Solution Structure of an Acyclic Precursor Peptide* , 2003, Journal of Biological Chemistry.

[33]  R. Leatherbarrow,et al.  The Structural Basis of a Conserved P2 Threonine in Canonical Serine Proteinase Inhibitors , 2003, Journal of biomolecular structure & dynamics.

[34]  L. Gráf,et al.  Natural Substrates and Inhibitors of Mannan-Binding Lectin-Associated Serine Protease-1 and -2: A Study on Recombinant Catalytic Fragments 1 , 2003, The Journal of Immunology.

[35]  W. Grabarse,et al.  Monomeric structures of the zymogen and active catalytic domain of complement protease c1r: further insights into the c1 activation mechanism. , 2002, Structure.

[36]  John D Lambris,et al.  Complement: more than a 'guard' against invading pathogens? , 2002, Trends in immunology.

[37]  Robert M Cooke,et al.  A conserved cis peptide bond is necessary for the activity of Bowman-Birk inhibitor protein. , 2002, Biochemistry.

[38]  A. Jaśkiewicz,et al.  Chemical synthesis and kinetic study of the smallest naturally occurring trypsin inhibitor SFTI-1 isolated from sunflower seeds and its analogues. , 2002, Biochemical and biophysical research communications.

[39]  K. Hajela,et al.  The biological functions of MBL-associated serine proteases (MASPs). , 2002, Immunobiology.

[40]  R. Leatherbarrow,et al.  Peptide mimics of the Bowman-Birk inhibitor reactive site loop. , 2002, Biopolymers.

[41]  J. Drijfhout,et al.  Specific Inhibition of the Classical Complement Pathway by C1q-Binding Peptides1 , 2001, The Journal of Immunology.

[42]  J. Jensenius,et al.  Substrate Specificities of Recombinant Mannan-binding Lectin-associated Serine Proteases-1 and -2* , 2001, The Journal of Biological Chemistry.

[43]  D. Craik,et al.  Solution structures by 1H NMR of the novel cyclic trypsin inhibitor SFTI-1 from sunflower seeds and an acyclic permutant. , 2001, Journal of molecular biology.

[44]  R. Wallis,et al.  Stoichiometry of Complexes between Mannose-binding Protein and Its Associated Serine Proteases , 2001, The Journal of Biological Chemistry.

[45]  M. Walport Complement. First of two parts. , 2001, The New England journal of medicine.

[46]  Michael C. Montalto,et al.  A Keratin Peptide Inhibits Mannose-Binding Lectin1 , 2001, The Journal of Immunology.

[47]  S. Thiel,et al.  Proteolytic Activities of Two Types of Mannose-Binding Lectin-Associated Serine Protease , 2000, The Journal of Immunology.

[48]  Dimitrios Morikis,et al.  Binding Kinetics, Structure-Activity Relationship, and Biotransformation of the Complement Inhibitor Compstatin1 , 2000, The Journal of Immunology.

[49]  G. Arlaud,et al.  Crystal structure of the catalytic domain of human complement C1s: a serine protease with a handle , 2000, The EMBO journal.

[50]  S. Sidhu,et al.  Phage display for selection of novel binding peptides. , 2000, Methods in enzymology.

[51]  S Luckett,et al.  High-resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds. , 1999, Journal of molecular biology.

[52]  R. Leatherbarrow,et al.  The role of the P2' position of Bowman-Birk proteinase inhibitor in the inhibition of trypsin. Studies on P2' variation in cyclic peptides encompassing the reactive site loop. , 1999, Biochimica et biophysica acta.

[53]  R. Leatherbarrow,et al.  The role of threonine in the P2 position of Bowman-Birk proteinase inhibitors: studies on P2 variation in cyclic peptides encompassing the reactive site loop. , 1998, Journal of molecular biology.

[54]  S. Philipp,et al.  Mutational analysis of disulfide bonds in the trypsin-reactive subdomain of a Bowman-Birk-type inhibitor of trypsin and chymotrypsin--cooperative versus autonomous refolding of subdomains. , 1998, European journal of biochemistry.

[55]  John D Lambris,et al.  Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. , 1996, Journal of immunology.

[56]  G. Fields,et al.  Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. , 2009, International journal of peptide and protein research.

[57]  G. P. Smith,et al.  Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.

[58]  M. Laskowski,et al.  Thermodynamics and kinetics of single residue replacements in avian ovomucoid third domains: effect on inhibitor interactions with serine proteinases. , 1982, Biochemistry.

[59]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.